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Abstract
Purpose—To investigate new genetic risk factors and replicate reported associations with 
advanced age related macular degeneration (AMD) in a prospective case - control study developed 
with a Spanish cohort.
Methods—Three hundred and fifty-three unrelated patients with advanced AMD (225 with 
atrophic AMD, 57 with neovascular AMD, and 71 with mixed AMD) and 282 age-matched 
controls were included. Functional and tagging SNPs in 55 candidate genes were genotyped using 
the SNPlex™ genotyping system. Single SNP and haplotype association analysis were performed 
to determine possible genetic associations; interaction effects between SNPs were also 
investigated.
Results—In agreement with previous reports, ARMS2 and CFH genes were strongly associated 
with AMD in the studied Spanish population. Moreover, both loci influenced risk independently 
giving support to different pathways implicated in AMD pathogenesis. No evidence for 
association of advanced AMD with other previous reported susceptibility genes, such as CST3, 
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CX3CR1, FBLN5, HMCN1, PON1, SOD2, TLR4, VEGF and VLDLR, was detected. However, 
two additional genes appear to be candidate markers for the development of advanced AMD. A 
variant located at the 3´UTR of the FGF2 gene (rs6820411) was highly associated with atrophic 
AMD, and the functional SNP rs3112831 at ABCA4 showed a marginal association with the 
disease.
Conclusion—We performed a large gene association study in advanced AMD in a Spanish 
population. Our findings show that CFH and ARMS2 genes seem to be the principal risk loci 
contributing independently to AMD in our cohort. We report new significant associations that 
could also influence the development of advanced AMD. These findings should be confirmed in 
further studies with larger cohorts.
Keywords
Age related macular degeneration; genetic association; case-control study; CFH; ARMS2; FGF2 
and ABCA4
Introduction
Age-related macular degeneration (AMD) is a late-onset, genetically complex disease that 
causes progressive damage to the macula. Early stages are characterized by the presence of 
small, intermediate or soft drusen and pigmentary abnormalities in the retinal pigment 
epithelium (RPE). Progression to advanced stage leads to loss of central vision after the 
development of two different types of late-stage lesions, choroidal neovascularization 
(CNV), associated with subretinal haemorrhage and scarring; or geographic atrophy (GA). 
Advanced AMD is the major cause of untreatable blindness in the Western 
countries(Friedman et al. 2004). Although neovascular AMD accounts for about 10% of 
AMD cases, it is responsible for more than 90% of legal blindness due to AMD (Jager et al. 
2008).
Several environmental, dietary, and genetic risk factors have been established for AMD 
development, including age, caucasian race, heredity, and smoking history (Seddon et al. 
1997; van Leeuwen et al. 2003). Smoking has been consistently established as a risk factor, 
resulting in about two- to three-fold increased risk of developing AMD in current-smokers 
compared with never-smokers (Thornton et al. 2005).
In recent years, major progress has been made in elucidating the AMD genetic basis through 
the identification of two major risk loci at 1q31 and 10q26, together accounting for above 
50% of AMD cases (Edwards et al. 2005; Klein et al. 2005). At 1q31, several risk variants 
and haplotypes in the complement factor H (CFH) gene have been strongly associated with 
early and advanced AMD, suggesting an involvement of immune-mediated complement 
pathway in AMD pathogenesis (Edwards et al. 2005; Hageman et al. 2005; Klein et al. 2005; 
Hageman et al. 2006; Hughes et al. 2006; Li et al. 2006). In addition, several complement 
genes have recently been also associated with AMD susceptibility, including complement 
factor B (CFB), complement 2 (C2), and complement 3 (C3) genes(Gold et al. 2006; Maller 
et al. 2007; Yates et al. 2007). Besides the complement pathway, the major genetics 
contributor to AMD risk lies in 10q26 locus at ARMS2/HTRA1 genes. Variants in this 
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region have been consistently reproducible across multiple ethnic groups (Jakobsdottir et al. 
2005; Rivera et al. 2005; Dewan et al. 2006; Schmidt et al. 2006; Tanimoto et al. 2007; 
Weger et al. 2007). To date, many candidate gene association studies have been carried out, 
describing several other minor susceptibility variants. However, those findings should be 
considered as inconclusive because of the lack of consistent replication in different 
populations (Swaroop et al. 2009). Despite this progress in AMD genetic research in the past 
few years, the total number of loci involved in AMD development and their account for the 
population attributable risk are far from being fully known. Identification of these genetic 
and environmental risk factors is the first step towards earlier detection, prevention, and in 
the future, better treatments.
To further investigate the genetic complexity of advanced AMD in Spain, we performed a 
large and comprehensive study of candidate genes for advanced AMD, including 350 
functional and tagging variants in 55 genes. Our aim was to identify new genetic risk factors, 
and to replicate the two major and other minor AMD risk loci previously reported. We 




A total of 353 case subjects with advanced AMD and 282 age-matched unrelated controls 
were recruited from ophthalmic clinics in fifteen hospitals from the Spanish multi-centre 
group of AMD. Subjects were all Caucasian and of Spanish descent.
The diagnosis of AMD was established on the basis of 35° colour pictures obtained of the 
macular area of each eye, after dilatation of pupils with tropicamide 0.5% and phenylephrine 
5%. Fundus photographs were graded according to the Age-Related Eye Disease Study 
(AREDS) classification for AMD by two trained professionals (2000). AMD patients were 
categorized into early and advanced AMD, according to status in the more severely affected 
eye. Briefly, early AMD (grade 2 and 3) was defined as the presence of either soft, distinct 
drusen with pigmentary irregularities, or soft, indistinct drusen with or without pigmentary 
irregularities. Advanced AMD (grade 4) was defined as atrophic, neovascular or mixed 
AMD. As this study focused on end-stage disease, patients with early AMD changes were 
excluded. Patients were classified in three subgroups: 225 subjects with atrophic AMD, 57 
subjects with neovascular AMD, and finally 71 patients with a mixed phenotype, with both 
geographic atrophy and choroidal neovascularization.
Age-matched controls were recruited from the same hospitals during routine ophthalmic 
examinations and were above 65 years of age. Control individuals had no evidence of drusen 
in either eye, macular or retinal disorder after ophthalmic examination, family relationship 
with the AMD cohort, or family history of maculopathies.
This study was conducted according to the recommendations of the Declaration of Helsinki 
and approved by the local ethics committees of the participating institutions. Signed 
informed consent was obtained from all subjects before inclusion in the study. Each 
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participant was given a short questionnaire about sex, smoking, refraction, medical history 
review, and familial history of AMD. Data on disease status, sex, age, and smoking history 
of subjects are provided in Table 1.
Candidate genes and SNPs Selection
Fifty-five candidate genes were selected on the basis of biological and genetics knowledge 
of AMD. We included genes involved in AMD pathogenic mechanisms, such as oxidative 
damage, chronic inflammation, complement regulation, RPE or photoreceptor death and 
angiogenesis regulation, by previous expression, knock-out, proteomic or biochemical 
studies (Mullins et al. 2000; Lambooij et al. 2003; Rakic et al. 2003; Hahn et al. 2004; 
Martin et al. 2004). We also selected some functional candidate genes located at several loci 
associated with the disease by previous genome-wide linkage studies, such as 1q32, 3q24-
q25, 4q27, 9q33, 12q23.2-24.31, 17q25.1, 19q13.31 (Majewski et al. 2003; Abecasis et al. 
2004; Weeks et al. 2004; Fisher et al. 2005; Jun et al. 2005; Barral et al. 2006). Finally, we 
also studied the two major risk loci for AMD, CFH and ARMS2 genes, and other putative 
susceptibility genes, such as ABCA4, APOE, CST3, CX3CR1, FBLN5, HMCN1, PON1, 
SOD2, TLR4, VEGFA and VLDLR. More information about the candidate genes and their 
selection are given in the Appendix.
Our aim was to examine common variations [Minor Allele Frequency (MAF) > 0.1] in the 
selected candidate genes for AMD predisposition. Single nucleotide polymorphisms (SNP) 
selection was based on functional variation and linkage disequilibrium (LD) data from the 
International HapMap Project [http://www.hapmap.org/] (HapMap 2003). First, we selected 
all known common non-synonymous coding SNPs deposited in the dbSNP database (Build 
126) [http://www.ncbi.nlm.nih.gov/SNP/index.html]. Second, we used FESD, a functional 
SNP Database [http://variome.kobic.re.kr/FESD/index.php] in order to prioritize putative 
regulatory SNPs (Kang et al. 2005). Finally, using genotypes and haplotypes from the 
HapMap Caucasian (CEU) population panel, tagSNPs were selected by using a tagging 
strategy with the Tagger tool implemented in Haploview (Barrett et al. 2005), using a strong 
LD tagging criteria of r2> 0.8 and with MAF > 10%. Each candidate gene was covered 
including an extended region of 10 kb upstream and downstream of the coding region.
Genotyping
Genomic DNA was isolated from peripheral blood using Wizard Genomic DNA Purification 
Kit (Promega). SNP genotyping was performed by the SNPlex™ genotyping system 
available in the Santiago node of the National Genotyping Centre of Spain (CEGEN) (Tobler 
et al. 2005). Genotyping assays were successfully designed for 380 SNPs using the assay 
design to the SNPlex System Bioinformatics Design Pipeline. SNPlex technology uses 
oligonucleotide ligation assay (OLA) combined with multiplex PCR technology to achieve 
allelic discrimination and target amplification. The final products are detected by capillary 
electrophoresis on 3730xl DNA Analyzer (Applied Biosystems) and analysed with 
GeneMapper v.4.0 (Applied Biosystems). As a quality control, we tested for any departure 
from Hardy–Weinberg equilibrium (HWE) in control samples (P>0.001).
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Quality measures taken into account for genotyped SNPs to be excluded from the 
subsequent analysis were: MAF<0.05, genotyping success <80% and failed Hardy-Weinberg 
equilibrium test in control samples (P>0.001).
Statistical analysis
Analyses of genotyping results were performed using several toolsets implemented in 
SNPator [http://www.snpator.com/] (Morcillo-Suarez et al. 2008), Haploview 4.0 [http://
www.broad.mit.edu/mpg/haploview/] (Barrett et al. 2005) and SNPassoc [http://cran.r-
project.org/web/packages/SNPassoc/index.html] software (Rakic et al. 2003). Mann-
Whitney U test was used to compare the ages of cases subjects and controls. Chi-square test 
was used to compare categorical variables and allele or haplotypes frequencies between 
AMD patients (or in the three AMD subgroups) and controls and to check for Hardy-
Weinberg equilibrium (HWE) in control group. Fisher’s exact test was used when allele 
counts were < 5 by convention. Likelihood ratio test was used to compare genotype 
frequencies and to investigate interaction effects between SNPs. Dominant, recessive and 
codominant models were considered and the Akaike information criteria (AIC) was used to 
choose the genetic model that best fits the data. Adjusted analyses by traditional risk factors 
of AMD (age, gender and smoking status) were done with logistic regression models. P 
values, odds ratios (ORs) and 95% confidence intervals are reported. To evaluate the 
significance of the genetic associations with AMD after adjustment for multiple testing, 
permutation correction was performed with the association tests of individual SNPs with 
10000 simulations (Corrected P<0.05 was considered as significant).
Linkage disequilibrium was assessed using both D´ and r2 measures implemented in 
Haploview. Haplotype inference was performed by the EM algorithm and haplotype blocks 
were generated by the algorithm and parameters of Gabriel (Gabriel et al. 2002). 
Permutation test was used to adjust for multiple testing.
Results
We genotyped 380 SNPs in 55 candidate genes in a Spanish population of 353 patients with 
advanced AMD and 282 age-matched control subjects. The mean age at examination was 
76.2 years for AMD patients (standard deviation [SD], 5.9 years; range, 52–96 years) and 
75.1 years for controls (SD, 5.8 years; range, 65-92 years). Although patients were slightly 
older than controls (P = 0.003), the other factors, such as the gender, smoking status, 
hypertension, diabetes mellitus, and atheromatous disease, did not differ between cases and 
controls.
Of the selected SNPs, 27 failed in the SNPlex Genotyping system, 14 had low genotyping 
call rate and 7 were monomorphic in our population. Therefore, these 48 of the 380 SNPs 
were not further studied. The success genotyping rate for the remaining SNPs was above 
92%. These were tested separately in case and control samples for any departure from the 
Hardy–Weinberg equilibrium. All the SNP were in Hardy–Weinberg equilibrium in controls 
samples (P > 0.001) with the exception of two SNPs (rs968451 and rs4858652), which were 
also excluded from further analyses.
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Association analysis was directly assessed with the 330 SNPs (Appendix) and adjusted 
analyses by age, gender and smoking status were also performed, with similar results (data 
not shown). After correction for multiple hypothesis testing through permutation analysis 
(corrected-P < 0.05), SNPs strongly associated with advanced AMD are compiled in Table 
2. Additional stratified analyses by AMD subphenotype (neovascular, atrophic or mixed 
AMD) were also performed and most of the above SNPs remained statistically significant in 
spite of the smaller number of atrophic and mixed AMD patients.
In agreement with previous reports, both ARMS2 and CFH genes were associated with 
AMD in Spanish population (de la Fuente et al. 2007; Recalde et al. 2008). Briefly, the T 
risk allele in the A69S variant (rs10490924) at ARMS2 gene showed the strongest 
association with late stage AMD (T allele, OR =3.94, P=1.75×10−25; ORhom = 12.64, ORhet 
= 4.19, P=3.19×10−21). As shown in Table 2, A69S confers similar risks to the three forms 
of advanced AMD. In the same way, seven alleles at CFH gene were also significantly 
associated with advanced AMD patients. Between them, two intronic tagging SNPs 
(rs1329428 and rs1329421) showed the strongest associations (OR=2.49, P=2.13×10−13 and 
OR= 2.04, P=8.12×10−10, respectively). When neovascular, atrophic and mixed AMD 
stratified analyses were performed, association with CFH gene remained. No epistatic 
interactions were detected between rs10490924 at ARMS2 gene and the two most 
significant SNPs at CFH gene based on the likelihood ratio test (Table 4).
In addition to the previously known risk variants of AMD, a tagging SNP (rs6820411) 
located 3′ of FGF2 (Fibroblast growth factor 2) was also associated with advanced AMD 
after permutation correction (allele A OR= 1.96, P=0.0043; OR AA+AC= 2.2, P=0.0076). 
Also, their effect remained significant after adjusting for other risk factors, including 
smoking status, age and polymorphisms in CFH and ARMS2 (data not shown). When 
phenotype subgroups were compared with controls, allele and genotype frequency 
differences were also found. Although the association remained significant only for atrophic 
AMD cases after correction for multiple testing, exudative and mixed AMD cases showed a 
trend toward association (Table 2). Epistatic interactions were not detected between 
rs6820411 at FGF2 and risk alleles in ARMS2 and CFH based on the likelihood ratio test, as 
shown in Table 5.
In order to replicate the putative effect of FGF2, the associated polymorphism in Spanish 
population was additionally genotyped in a total of 609 AMD cases and 325 healthy 
Caucasian subjects from US (Swaroop). No evidence of association was found in this cohort 
(allele association P = 0.17).
Additionally, two variants showed a lesser extent of association with advanced AMD after a 
multiple testing correction. A functional SNP at ABCA4 gene (rs3112831) had a marginal 
association (P=0.0015) with advanced AMD. rs2384571, and a tagSNP located in CGREF1 
gene, had also shown a significant association but only for atrophic AMD patients 
(P=0.0045).
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To determine whether any of the haplotypes in the candidate genes could be associated with 
AMD, linkage disequilibrium (LD) analysis and haplotype estimation were performed. 
Haplotype analysis did not detect any association in the additional candidate genes, only 
CFH and FGF2 haplotypes showed a strong evidence of association with late AMD after 
correcting for multiple testing (corrected-P < 0.05). The association between the haplotype 
carrying risk alleles was either equal or weaker than the association at each individual SNP.
In concordance with previous reports, CFH region showed extensive LD in our population, 
as shown in Figure 1. Except for rs800292, all SNPs at CFH gene were included in a large 
LD block. Haplotype estimation in CFH gene in cases and controls identified a common risk 
haplotype (H1) in 50% of AMD cases versus 35% of controls (OR= 1.99, P<10−9) and three 
protective haplotypes (H3, H4 and H5), as shown in Figure 1. All of them showed a strong 
association with AMD in the overall dataset and in the three AMD subgroups (data not 
shown). The two most associated SNPs at single-marker analysis contained alleles that 
mainly distinguished between risk and protective haplotypes. The T allele at rs1329421 and 
the A allele at rs1329428 were exclusively found in the risk and protective haplotypes, 
respectively.
In the analysis of LD map at FGF2 locus (Figure 2), a small haplotype block of 2 SNPs was 
found upstream of the gene. Those SNPs were not associated with AMD; however, an 
extensive LD region was found between the 3′ part of the FGF2 gene and downstream 
region, comprising NUDT6 gene. Haploview showed six more frequent haplotypes in the 
analysed population and only one of them (H3) included the risk allele at rs6820411. After 
multiple testing correction, only this haplotype was significantly associated with AMD risk 
(OR= 1.83, P<10−4).
Discussion
We designed a functional and tagging SNP selection strategy in 55 candidate genes, selected 
in basis of positional criteria, their contribution to AMD aetiology, and/or their previous 
implication as risk variant. We determined whether common variations across the candidate 
genes displayed significant association with advanced AMD or their three phenotypic 
subgroups (neovascular, atrophic or mixed AMD) in a Spanish population.
Despite using a different set of CFH variants than most of the published studies, our results 
in Spanish population are in agreement with previous reports in other Caucasian cohorts 
(Hageman et al. 2005; Klein et al. 2005; Li et al. 2006; Francis et al. 2007). Seven of eight 
tagSNPs here studied were associated with advanced AMD. Only rs1065489, a missense 
variant, did not show any evidence of association, as previously reported by Hageman et al 
(Hageman et al. 2005). rs1329421 and rs1329428, located in the CFH introns 7 and 15, 
respectively, exhibited the strongest association with AMD in our Spanish cohort. With the 
exception of rs1329421, all significant variants at CFH gene were previously described as 
associated to AMD (Hageman et al. 2005; Klein et al. 2005; Li et al. 2006; Francis et al. 
2007).
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The strong linkage disequilibrium present in this region makes it difficult to distinguish the 
causal variant of another in linkage disequilibrium with it. Although CFH Y402H could play 
a causal role in the development of AMD, as postulated by several reports (Skerka et al. 
2007; Yu et al. 2007; Ormsby et al. 2008), also other variants could increase the risk of 
AMD by regulating the expression of CFH or CFH-related genes located within the RCA 
(Regulation of Complement Activation) locus on chromosome 1. In our Spanish AMD 
cohort, we could also found a set of common susceptibility and protective haplotypes against 
AMD, as previously observed in other Caucasian population. Those haplotypes were defined 
by 7 SNPs, and two of them, T allele at rs1329421 and the A allele at rs1329428 were 
exclusively found in the risk and protective haplotypes, respectively.
Although we could not asses the AMD risk associated with CFH Y402H due to a 
unsuccessful genotyping assay with SNPlex platform, we could previously report a risk 
effect on advanced AMD in a preliminary study with 175 AMD cases and 119 controls (de 
la Fuente et al. 2007). When we considered only common samples analysed in both cohorts, 
Y402H variant showed a strong LD with rs1329421 and rs1831282 (r2 = 0.98 and 0.92, 
respectively). The risk-associated C-allele of the Y402H variant was found to take part of 
the risk haplotype H1 (data not shown). Therefore, our 7-SNP haplotype seems to fit well 
with risk haplotypes described in other Caucasian populations.
Our results showed that significant CFH polymorphisms overall associate with a similar 
frequency with the neovascular, atrophic and mixed AMD subtypes. Neither single variants 
nor risk haplotype preferentially increased susceptibility to one of these 3 phenotypes. In our 
report, we did not include early or intermediate stages of AMD; so, whether those 
polymorphisms also contribute to earlier AMD phenotypes remains to be fully explored.
Our findings also confirm ARMS2 as another principal contributor to advanced AMD risk in 
Spanish population (Kanda et al. 2007; Fritsche et al. 2008), (de la Fuente et al. 2007; 
Recalde et al. 2008). In agreement with previous studies, we could not identify gene 
interaction between CFH and ARMS2. Thus, the A69S polymorphism in ARMS2 is 
strongly associated with advanced AMD in an independent extent of the CFH 
polymorphisms.
With regard to the rest of gene variants studied here, most of them did not show allelic or 
genotype frequency differences between AMD cases and controls. Only rs6820411 at FGF2 
gene and rs3112831 at ABCA4 gene maintained statistical significance after multiple testing 
correction.
Fibroblast growth factor 2 (FGF2) is a widely expressed protein with potent angiogenic 
activity that promotes growth and differentiation of a broad spectrum of cell types. FGF2 
seem to play also an essential role in VEGF-dependent choroidal neovascularisation (Frank 
1997; Browning et al. 2008). It was found in high concentration in neovascular tissue in 
AMD patients and up-regulated in laser-induced choroidal neovascularisation (Ogata et al. 
1996; Cameron et al. 2007). In our study, we found a strong association between advanced 
AMD and rs6820411 even after adjusting for age, sex, smoking, CFH or ARMS2 risk 
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variants. In addition, when endophenotypes were considered, significant association with 
atrophic AMD was also maintained after multiple testing corrections.
rs6820411 is located downstream of FGF2 in the promoter region of NUDT6 gene, which is 
transcribed in the opposite direction (Figure 2). NUDT6 transcription generates an 
overlapping antisense RNA (FGF-AS) implicated in the post-transcriptional regulation of 
FGF-2 expression and function (Baguma-Nibasheka et al. 2007). HapMap Phase II data 
shows a large extent of LD as the 3′ FGF2/FGF-AS region, making possible that rs6820411 
being in LD with a non-assayed causal variant at FGF-AS. The lack of replication in an 
admixed US population with patients at early and advanced AMD stages could be reflecting 
a population and phenotype-dependence of this variant on AMD susceptibility. 
Epidemiological studies have revealed differences in the prevalence of advanced AMD 
among different ethnic groups with major rates in Caucasian than African and Asian 
individuals (2000). As HapMap data showed, rs6820411 is only polymorphic in Caucasian 
(CEU) population. In addition, despite showing positive association with general AMD in 
our study, when subclinical forms of the disease were considered, the putative risk allele was 
only detected in the atrophic forms. Consequently, further resequencing and association 
analyses of FGF2/FGF-AS region in a larger cohort, phenotypically well characterized in the 
different clinical AMD phenotypes, are needed to confirm the putative role of FGF-AS in 
AMD susceptibility.
ABCA4 is the retina-specific ABC transporter gene and responsible for the Stargardt 
disease, an autosomal recessive form of juvenile macular degeneration. We observed a 
marginal allelic association with the missense H423R variant (rs3112831) with advanced 
AMD. Although some authors reported mutations in ABCA4 gene in a small percentage of 
AMD cases (Allikmets et al. 1997; Shroyer et al. 2001), most of the studies reported no 
statistical significant association (Rivera et al. 2000; Souied et al. 2000; Guymer et al. 2001; 
Schmidt et al. 2003). In a similar way, we observed some marginal significant association 
with two variants at CGREF1 and APOE variants with atrophic and mixed AMD forms. 
Additionally studies are needed with larger cohorts to confirm those observations.
We could not detect statistically significant association in our population between other 
minor susceptibility genes and advanced AMD, such as CST3, CX3CR1, FBLN5, HMCN1, 
PON1, SOD2, TLR4, VEGFA and VLDLR, in agreement with other reports (Schultz et al. 
2003; Abecasis et al. 2004; Baird et al. 2004; Hayashi et al. 2004; Bojanowski et al. 2005; 
Esfandiary et al. 2005; Schmidt et al. 2005; Fuse et al. 2006; Kaur et al. 2006; Seitsonen et 
al. 2006; Fisher et al. 2007; Richardson et al. 2007; Despriet et al. 2008; Edwards et al. 
2008; Utheim et al. 2008). Discrepancies in replication of risk variants in association studies 
could be caused by population heterogeneity, disease heterogeneity, and/or the use of 
different diagnostic criteria among cases, but it could also reflect the lack of power to detect 
modest gene effects with undersized samples. With our sample size, the study reached >80% 
power at a 5% significance level to detect an odds ratio greater than 1.52 when the allele 
frequency is 0.05, or an OR > 1.26 for an allele at a frequency of 30%. Since we only 
examined for association advanced stages of AMD in our study, it could be possible that 
some of these candidates genes are only associated with the early forms of AMD.
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Recently, other risk and protective variants on complement genes have been strongly 
associated with AMD; however, they could not be assessed here because the study design 
and genotyping were performed before the variants in these loci were confirmed as risk and 
protective factors.
In summary, we have replicated the CFH and ARMS2 gene variants association with 
advanced AMD in the Spanish population. Moreover, as it was previously reported 
(Deangelis et al. 2008), both loci influence risk independently, giving support to different 
pathways implicated in the pathogenesis of the disease. No evidence for a role of other 
previously reported genes in the development of AMD was found. Nevertheless, more 
extended studies should be performed in order to role out the effect of these genes taking 
into account different groups of populations and possible interactions with other genetic or 
environmental factors. Finally, although we have identified a gene variant (rs6820411) 
within the downstream region of the FGF2 locus, with a novel hypothetical role in the 
pathogenesis of AMD, we could not replicate our findings in a matched US American set of 
samples. Validation of the putative effect of this variant deserves further analysis in an 
extended group of late AMD patients with European descent, well characterized in the 
different clinical forms of the disease.
Acknowledgments
We greatly thanks all the members of the Spanish multi-centre group of AMD: A.García Layana, Clínica 
Universitaria de Pamplona, Navarra; B. Pazos González, Instituto Gallego de Oftalmologia, Santiago de 
Compostela; M. Díaz Llopis, Hospital Universitario la Fe, Valencia; C. Torrón, Hospital Universitario Miguel 
Servet, Zaragoza; R. Coco, IOBA, Valladolid; F. Martínez, Hospital Marques de Valdecilla, Santander; J. Arraiz, 
Instituto Clínico Quirúrgico de Oftalmología, Bilbao; J. M. Ruiz Moreno, Vissum Instituto Oftalmológico, 
Alicante; C. Desco Esteban, Fundación Oftalmológica del Mediterráneo, Valencia; E. Esteban, Hospital Virgen de 
la Macarena, Sevilla; M.S. Figueroa, Hospital Ramón y Cajal, Madrid; F. Gómez-Ulla, Hospital Clínico 
Universitario de Santiago de Compostela; J. Bañuela Bañuela, Hospital de Alcorcón, Madrid; B. Fernández-Vega 
Sanz, Instituto Oftalmológico Fernández Vega, Asturias; L. Arias, Hospital Universitario de Bellvitge, Barcelona; 
and J. Fernández Vigo, Facultad Medicina, Universidad de Extremadura.
The study was supported by grants from the Xunta de Galicia (PGIDIT06PXIB208204PR), the Instituto de Salud 
Carlos III (EMER07/018), and National Institutes of Health, USA. The sponsor or funding organization had no role 
in the design or conduct of this research.
References
Risk factors associated with age-related macular degeneration. A case-control study in the age-related 
eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000; 
107:2224–32. [PubMed: 11097601] 
Abecasis GR, Yashar BM, Zhao Y, Ghiasvand NM, Zareparsi S, Branham KE, Reddick AC, Trager 
EH, Yoshida S, Bahling J, Filippova E, Elner S, Johnson MW, Vine AK, Sieving PA, Jacobson SG, 
Richards JE, Swaroop A. Age-related macular degeneration: a high-resolution genome scan for 
susceptibility loci in a population enriched for late-stage disease. Am J Hum Genet. 2004; 74:482–
94. [PubMed: 14968411] 
Allikmets R, Shroyer NF, Singh N, Seddon JM, Lewis RA, Bernstein PS, Peiffer A, Zabriskie NA, Li 
Y, Hutchinson A, Dean M, Lupski JR, Leppert M. Mutation of the Stargardt disease gene (ABCR) 
in age-related macular degeneration. Science. 1997; 277:1805–7. [PubMed: 9295268] 
Baguma-Nibasheka M, Li AW, Murphy PR. The fibroblast growth factor-2 antisense gene inhibits 
nuclear accumulation of FGF-2 and delays cell cycle progression in C6 glioma cells. Mol Cell 
Endocrinol. 2007; 267:127–36. [PubMed: 17306451] 
Brión et al. Page 10













Baird PN, Chu D, Guida E, Vu HT, Guymer R. Association of the M55L and Q192R paraoxonase gene 
polymorphisms with age-related macular degeneration. Am J Ophthalmol. 2004; 138:665–6. 
[PubMed: 15488805] 
Barral S, Francis PJ, Schultz DW, Schain MB, Haynes C, Majewski J, Ott J, Acott T, Weleber RG, 
Klein ML. Expanded genome scan in extended families with age-related macular degeneration. 
Invest Ophthalmol Vis Sci. 2006; 47:5453–9. [PubMed: 17122136] 
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype 
maps. Bioinformatics. 2005; 21:263–5. [PubMed: 15297300] 
Bojanowski CM, Tuo J, Chew EY, Csaky KG, Chan CC. Analysis of Hemicentin-1, hOgg1, and E-
selectin single nucleotide polymorphisms in age-related macular degeneration. Trans Am 
Ophthalmol Soc. 2005; 103:37–44. discussion 44-5. [PubMed: 17057786] 
Browning AC, Dua HS, Amoaku WM. The effects of growth factors on the proliferation and in vitro 
angiogenesis of human macular inner choroidal endothelial cells. Br J Ophthalmol. 2008; 92:1003–
8. [PubMed: 18577655] 
Cameron DJ, Yang Z, Gibbs D, Chen H, Kaminoh Y, Jorgensen A, Zeng J, Luo L, Brinton E, Brinton 
G, Brand JM, Bernstein PS, Zabriskie NA, Tang S, Constantine R, Tong Z, Zhang K. HTRA1 
variant confers similar risks to geographic atrophy and neovascular age-related macular 
degeneration. Cell Cycle. 2007; 6:1122–5. [PubMed: 17426452] 
de la Fuente M, Blanco MJ, Pazos B, Fernandez MI, Carracedo A, Sanchez-Salorio M, Coco RM, 
Torron C, Gomez AM. Complement factor H. Ophthalmology. 2007; 114:193 e1–2. [PubMed: 
17198855] 
Deangelis MM, Ji F, Adams S, Morrison MA, Harring AJ, Sweeney MO, Capone A Jr, Miller JW, 
Dryja TP, Ott J, Kim IK. Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular 
age-related macular degeneration. Ophthalmology. 2008; 115:1209–1215 e7. [PubMed: 18164066] 
Despriet DD, Bergen AA, Merriam JE, Zernant J, Barile GR, Smith RT, Barbazetto IA, van Soest S, 
Bakker A, de Jong PT, Allikmets R, Klaver CC. Comprehensive analysis of the candidate genes 
CCL2, CCR2, and TLR4 in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008; 
49:364–71. [PubMed: 18172114] 
Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, Tam PO, Chan WM, Lam DS, Snyder M, 
Barnstable C, Pang CP, Hoh J. HTRA1 promoter polymorphism in wet age-related macular 
degeneration. Science. 2006; 314:989–92. [PubMed: 17053108] 
Edwards AO, Chen D, Fridley BL, James KM, Wu Y, Abecasis G, Swaroop A, Othman M, Branham 
K, Iyengar SK, Sivakumaran TA, Klein R, Klein BE, Tosakulwong N. Toll-like receptor 
polymorphisms and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008; 49:1652–
9. [PubMed: 18385087] 
Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H 
polymorphism and age-related macular degeneration. Science. 2005; 308:421–4. [PubMed: 
15761121] 
Esfandiary H, Chakravarthy U, Patterson C, Young I, Hughes AE. Association study of detoxification 
genes in age related macular degeneration. Br J Ophthalmol. 2005; 89:470–4. [PubMed: 
15774926] 
Fisher SA, Abecasis GR, Yashar BM, Zareparsi S, Swaroop A, Iyengar SK, Klein BE, Klein R, Lee 
KE, Majewski J, Schultz DW, Klein ML, Seddon JM, Santangelo SL, Weeks DE, Conley YP, Mah 
TS, Schmidt S, Haines JL, Pericak-Vance MA, Gorin MB, Schulz HL, Pardi F, Lewis CM, Weber 
BH. Meta-analysis of genome scans of age-related macular degeneration. Hum Mol Genet. 2005; 
14:2257–64. [PubMed: 15987700] 
Fisher SA, Rivera A, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Rudolph G, Weber BH. 
Case-control genetic association study of fibulin-6 (FBLN6 or HMCN1) variants in age-related 
macular degeneration (AMD). Hum Mutat. 2007; 28:406–13. [PubMed: 17216616] 
Francis PJ, Schultz DW, Hamon S, Ott J, Weleber RG, Klein ML. Haplotypes in the complement 
factor H (CFH) gene: associations with drusen and advanced age-related macular degeneration. 
PLoS ONE. 2007; 2:e1197. [PubMed: 18043728] 
Frank RN. Growth factors in age-related macular degeneration: pathogenic and therapeutic 
implications. Ophthalmic Res. 1997; 29:341–53. [PubMed: 9323725] 
Brión et al. Page 11













Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, 
Kempen J. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 
2004; 122:564–72. [PubMed: 15078675] 
Fritsche LG, Loenhardt T, Janssen A, Fisher SA, Rivera A, Keilhauer CN, Weber BH. Age-related 
macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet. 
2008; 40:892–6. [PubMed: 18511946] 
Fuse N, Miyazawa A, Mengkegale M, Yoshida M, Wakusawa R, Abe T, Tamai M. Polymorphisms in 
Complement Factor H and Hemicentin-1 genes in a Japanese population with dry-type age-related 
macular degeneration. Am J Ophthalmol. 2006; 142:1074–6. [PubMed: 17157600] 
Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, 
Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, 
Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science. 2002; 
296:2225–9. [PubMed: 12029063] 
Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile 
GR, Smith RT, Hageman GS, Dean M, Allikmets R. Variation in factor B (BF) and complement 
component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006; 
38:458–62. [PubMed: 16518403] 
Guymer RH, Heon E, Lotery AJ, Munier FL, Schorderet DF, Baird PN, McNeil RJ, Haines H, 
Sheffield VC, Stone EM. Variation of codons 1961 and 2177 of the Stargardt disease gene is not 
associated with age-related macular degeneration. Arch Ophthalmol. 2001; 119:745–51. [PubMed: 
11346402] 
Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman 
HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang 
S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, 
Gold B, Dean M, Allikmets R. A common haplotype in the complement regulatory gene factor H 
(HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S 
A. 2005; 102:7227–32. [PubMed: 15870199] 
Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, Radeke MJ, Kavanagh 
D, Richards A, Atkinson J, Meri S, Bergeron J, Zernant J, Merriam J, Gold B, Allikmets R, Dean 
M. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of 
genes protect against age-related macular degeneration: characterization, ethnic distribution and 
evolutionary implications. Ann Med. 2006; 38:592–604.
Hahn P, Qian Y, Dentchev T, Chen L, Beard J, Harris ZL, Dunaief JL. Disruption of ceruloplasmin and 
hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-
related macular degeneration. Proc Natl Acad Sci U S A. 2004; 101:13850–5. [PubMed: 
15365174] 
HapMap CI. The International HapMap Project. Nature. 2003; 426:789–96. [PubMed: 14685227] 
Hayashi M, Merriam JE, Klaver CC, Zernant J, Bergen AA, Smith RT, Chang S, Merriam JC, 
Allikmets R. Evaluation of the ARMD1 locus on 1q25-31 in patients with age-related 
maculopathy: genetic variation in laminin genes and in exon 104 of HEMICENTIN-1. Ophthalmic 
Genet. 2004; 25:111–9. [PubMed: 15370542] 
Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH 
haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related 
macular degeneration. Nat Genet. 2006; 38:1173–7. [PubMed: 16998489] 
Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008; 358:2606–
17. [PubMed: 18550876] 
Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-
related maculopathy on chromosome 10q26. Am J Hum Genet. 2005; 77:389–407. [PubMed: 
16080115] 
Jun G, Klein BE, Klein R, Fox K, Millard C, Capriotti J, Russo K, Lee KE, Elston RC, Iyengar SK. 
Genome-wide analyses demonstrate novel loci that predispose to drusen formation. Invest 
Ophthalmol Vis Sci. 2005; 46:3081–8. [PubMed: 16123405] 
Kanda A, Chen W, Othman M, Branham KE, Brooks M, Khanna R, He S, Lyons R, Abecasis GR, 
Swaroop A. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly 
Brión et al. Page 12













associated with age-related macular degeneration. Proc Natl Acad Sci U S A. 2007; 104:16227–
32. [PubMed: 17884985] 
Kang HJ, Choi KO, Kim BD, Kim S, Kim YJ. FESD: a Functional Element SNPs Database in human. 
Nucleic Acids Res. 2005; 33:D518–22. [PubMed: 15608252] 
Kaur I, Hussain A, Hussain N, Das T, Pathangay A, Mathai A, Hussain A, Nutheti R, Nirmalan PK, 
Chakrabarti S. Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His 
variant of CFH to be a global marker for age-related macular degeneration. Invest Ophthalmol Vis 
Sci. 2006; 47:3729–35. [PubMed: 16936080] 
Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, 
Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. Complement factor H 
polymorphism in age-related macular degeneration. Science. 2005; 308:385–9. [PubMed: 
15761122] 
Lambooij AC, van Wely KH, Lindenbergh-Kortleve DJ, Kuijpers RW, Kliffen M, Mooy CM. Insulin-
like growth factor-I and its receptor in neovascular age-related macular degeneration. Invest 
Ophthalmol Vis Sci. 2003; 44:2192–8. [PubMed: 12714661] 
Li M, Atmaca-Sonmez P, Othman M, Branham KE, Khanna R, Wade MS, Li Y, Liang L, Zareparsi S, 
Swaroop A, Abecasis GR. CFH haplotypes without the Y402H coding variant show strong 
association with susceptibility to age-related macular degeneration. Nat Genet. 2006; 38:1049–54. 
[PubMed: 16936733] 
Majewski J, Schultz DW, Weleber RG, Schain MB, Edwards AO, Matise TC, Acott TS, Ott J, Klein 
ML. Age-related macular degeneration–a genome scan in extended families. Am J Hum Genet. 
2003; 73:540–50. [PubMed: 12900797] 
Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement 
factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007; 39:1200–1. 
[PubMed: 17767156] 
Martin G, Schlunck G, Hansen LL, Agostini HT. Differential expression of angioregulatory factors in 
normal and CNV-derived human retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol. 
2004; 242:321–6. [PubMed: 14722782] 
Morcillo-Suarez C, Alegre J, Sangros R, Gazave E, de Cid R, Milne R, Amigo J, Ferrer-Admetlla A, 
Moreno-Estrada A, Gardner M, Casals F, Perez-Lezaun A, Comas D, Bosch E, Calafell F, 
Bertranpetit J, Navarro A. SNP analysis to results (SNPator): a web-based environment oriented to 
statistical genomics analyses upon SNP data. Bioinformatics. 2008; 24:1643–4. [PubMed: 
18515823] 
Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related 
macular degeneration contain proteins common to extracellular deposits associated with 
atherosclerosis, elastosis, amyloidosis, and dense deposit disease. Faseb J. 2000; 14:835–46. 
[PubMed: 10783137] 
Ogata N, Matsushima M, Takada Y, Tobe T, Takahashi K, Yi X, Yamamoto C, Yamada H, Uyama M. 
Expression of basic fibroblast growth factor mRNA in developing choroidal neovascularization. 
Curr Eye Res. 1996; 15:1008–18. [PubMed: 8921239] 
Ormsby RJ, Ranganathan S, Tong JC, Griggs KM, Dimasi DP, Hewitt AW, Burdon KP, Craig JE, Hoh 
J, Gordon DL. Functional and structural implications of the complement factor H Y402H 
polymorphism associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008; 
49:1763–70. [PubMed: 18263814] 
Rakic JM, Lambert V, Munaut C, Bajou K, Peyrollier K, Alvarez-Gonzalez ML, Carmeliet P, Foidart 
JM, Noel A. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal 
neovascularization. Invest Ophthalmol Vis Sci. 2003; 44:1732–9. [PubMed: 12657615] 
Recalde S, Fernandez-Robredo P, Altarriba M, Salinas-Alaman A, Garcia-Layana A. Age-related 
macular degeneration genetics. Ophthalmology. 2008; 115:916–916 e1. [PubMed: 18452766] 
Richardson AJ, Islam FM, Guymer RH, Cain M, Baird PN. A tag-single nucleotide polymorphisms 
approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. 
Mol Vis. 2007; 13:2148–52. [PubMed: 18079689] 
Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH. Hypothetical 
LOC387715 is a second major susceptibility gene for age-related macular degeneration, 
Brión et al. Page 13













contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005; 
14:3227–36. [PubMed: 16174643] 
Rivera A, White K, Stohr H, Steiner K, Hemmrich N, Grimm T, Jurklies B, Lorenz B, Scholl HP, 
Apfelstedt-Sylla E, Weber BH. A comprehensive survey of sequence variation in the ABCA4 
(ABCR) gene in Stargardt disease and age-related macular degeneration. Am J Hum Genet. 2000; 
67:800–13. [PubMed: 10958763] 
Schmidt S, Haines JL, Postel EA, Agarwal A, Kwan SY, Gilbert JR, Pericak-Vance MA, Scott WK. 
Joint effects of smoking history and APOE genotypes in age-related macular degeneration. Mol 
Vis. 2005; 11:941–9. [PubMed: 16288198] 
Schmidt S, Hauser MA, Scott WK, Postel EA, Agarwal A, Gallins P, Wong F, Chen YS, Spencer K, 
Schnetz-Boutaud N, Haines JL, Pericak-Vance MA. Cigarette smoking strongly modifies the 
association of LOC387715 and age-related macular degeneration. Am J Hum Genet. 2006; 
78:852–64. [PubMed: 16642439] 
Schmidt S, Postel EA, Agarwal A, Allen IC Jr, Walters SN, De la Paz MA, Scott WK, Haines JL, 
Pericak-Vance MA, Gilbert JR. Detailed analysis of allelic variation in the ABCA4 gene in age-
related maculopathy. Invest Ophthalmol Vis Sci. 2003; 44:2868–75. [PubMed: 12824224] 
Schultz DW, Klein ML, Humpert A, Majewski J, Schain M, Weleber RG, Ott J, Acott TS. Lack of an 
association of apolipoprotein E gene polymorphisms with familial age-related macular 
degeneration. Arch Ophthalmol. 2003; 121:679–83. [PubMed: 12742846] 
Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J 
Ophthalmol. 1997; 123:199–206. [PubMed: 9186125] 
Seitsonen S, Lemmela S, Holopainen J, Tommila P, Ranta P, Kotamies A, Moilanen J, Palosaari T, 
Kaarniranta K, Meri S, Immonen I, Jarvela I. Analysis of variants in the complement factor H, the 
elongation of very long chain fatty acids-like 4 and the hemicentin 1 genes of age-related macular 
degeneration in the Finnish population. Mol Vis. 2006; 12:796–801. [PubMed: 16885922] 
Shroyer NF, Lewis RA, Yatsenko AN, Wensel TG, Lupski JR. Cosegregation and functional analysis 
of mutant ABCR (ABCA4) alleles in families that manifest both Stargardt disease and age-related 
macular degeneration. Hum Mol Genet. 2001; 10:2671–8. [PubMed: 11726554] 
Skerka C, Lauer N, Weinberger AA, Keilhauer CN, Suhnel J, Smith R, Schlotzer-Schrehardt U, 
Fritsche L, Heinen S, Hartmann A, Weber BH, Zipfel PF. Defective complement control of factor 
H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol. 2007; 44:3398–406. 
[PubMed: 17399790] 
Souied EH, Ducroq D, Rozet JM, Gerber S, Perrault I, Munnich A, Coscas G, Soubrane G, Kaplan J. 
ABCR gene analysis in familial exudative age-related macular degeneration. Invest Ophthalmol 
Vis Sci. 2000; 41:244–7. [PubMed: 10634626] 
Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial late-onset disease: from 
genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev 
Genomics Hum Genet. 2009; 10:19–43. [PubMed: 19405847] 
Tanimoto S, Tamura H, Ue T, Yamane K, Maruyama H, Kawakami H, Kiuchi Y. A polymorphism of 
LOC387715 gene is associated with age-related macular degeneration in the Japanese population. 
Neurosci Lett. 2007; 414:71–4. [PubMed: 17194541] 
Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related 
macular degeneration: a review of association. Eye. 2005; 19:935–44. [PubMed: 16151432] 
Tobler AR, Short S, Andersen MR, Paner TM, Briggs JC, Lambert SM, Wu PP, Wang Y, Spoonde AY, 
Koehler RT, Peyret N, Chen C, Broomer AJ, Ridzon DA, Zhou H, Hoo BS, Hayashibara KC, 
Leong LN, Ma CN, Rosenblum BB, Day JP, Ziegle JS, De La Vega FM, Rhodes MD, Hennessy 
KM, Wenz HM. The SNPlex genotyping system: a flexible and scalable platform for SNP 
genotyping. J Biomol Tech. 2005; 16:398–406. [PubMed: 16522862] 
Utheim OA, Ritland JS, Utheim TP, Espeseth T, Lydersen S, Rootwelt H, Semb SO, Elsas T. 
Apolipoprotein E genotype and risk for development of cataract and age-related macular 
degeneration. Acta Ophthalmol. 2008; 86:401–3. [PubMed: 18498549] 
van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-
related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol. 2003; 
121:519–26. [PubMed: 12695249] 
Brión et al. Page 14













Weeks DE, Conley YP, Tsai HJ, Mah TS, Schmidt S, Postel EA, Agarwal A, Haines JL, Pericak-Vance 
MA, Rosenfeld PJ, Paul TO, Eller AW, Morse LS, Dailey JP, Ferrell RE, Gorin MB. Age-related 
maculopathy: a genomewide scan with continued evidence of susceptibility loci within the 1q31, 
10q26, and 17q25 regions. Am J Hum Genet. 2004; 75:174–89. [PubMed: 15168325] 
Weger M, Renner W, Steinbrugger I, Kofer K, Wedrich A, Groselj-Strele A, El-Shabrawi Y, Schmut O, 
Haas A. Association of the HTRA1 -625G>A promoter gene polymorphism with exudative age-
related macular degeneration in a Central European population. Mol Vis. 2007; 13:1274–9. 
[PubMed: 17679948] 
Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, Clayton DG, Hayward C, Morgan J, 
Wright AF, Armbrecht AM, Dhillon B, Deary IJ, Redmond E, Bird AC, Moore AT. Complement 
C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007; 357:553–61. 
[PubMed: 17634448] 
Yu J, Wiita P, Kawaguchi R, Honda J, Jorgensen A, Zhang K, Fischetti VA, Sun H. Biochemical 
analysis of a common human polymorphism associated with age-related macular degeneration. 
Biochemistry. 2007; 46:8451–61. [PubMed: 17580967] 
Brión et al. Page 15













Figure 1. LD and haplotype maps of the CFH locus in this Spanish population
A schematic representation of the intron/exon structure of the CFH gene is indicated above 
the LD plot. Relative positions of studied SNPs are also indicated. Each box provides r2 
values with darker red shades representing stronger LD. Haplotype association analysis in 
cases and controls were performed for the single haplotype block found at this locus. All of 
the haplotypes with a frequency of >1% are displayed. The estimated frequencies of the 
haplotype in cases and controls, ORs, 95% CI and P-values are also shown. The risk 
haplotype (H1) is shown in red shading, and the protective haplotypes (H3, H4 and H5) are 
shown in green shading. Alleles exclusively found in these risk and protective haplotypes are 
boxed.
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Figure 2. LD and haplotype maps of the FGF2 locus in this Spanish population
A schematic representation of the intron/exon structure of the FGF2 and NUDT6 genes with 
the relative positions of tagSNPs, is indicated above the LD plot. Each box provides r2 
values with darker red shades representing stronger LD. Haplotype association analysis in 
cases and controls are also performed on the two haplotype blocks found at this locus. All of 
the haplotypes with a frequency of >1% are displayed. The estimated haplotypic frequencies 
Brión et al. Page 17













in cases and controls, P-values, ORs and 95% CI are also shown. The risk haplotype (H3) is 
shown in red shading remarking in a box the risk allele at rs6820411.
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Table 1
Baseline characteristics of Age-Related Macular Degeneration patients and controls
Variable Controls (N=282) Cases (N=353) p-value
Afection status no. (%)
No AMD 282
Neovascular AMD 225 (63.7)
Geographic atrophy 57 (16.2)
Mixed AMD 71 (20.1)
Sex no. (%)
Male 126 (44.7) 163 (46.2) 0.707
Female 156 (55.3) 190 (53.82)
Mean age (SD) 75.1 (5.8) 76.74 (5.82) 0.003
Smoking history no. (%)
No. of subjects 278 344 0.134
Never smoked 209 (75.2) 240 (69.8)
Current or former smoker 69 (24.8) 104 (30.2)
HTA no. (%)
No. of subjects 280 348 0.983
no 133 (47.5) 165 (47.4)
yes 147 (52.5) 183 (52.6)
Diabetes mellitus no. (%)
No. of subjects 281 348 0.874
no 241 (85.8) 300 (86.2)
yes 40 (14.23) 48 (13.8)
Atheromatous disease no. (%)
No. of subjects 280 345
no 226 (80.7) 269 (78)
Ischemic cardiopathy 32 (11.4) 44 (13) 0.568
Ischemic stroke 6 (2.1) 12 (3.6) 0.297
Peripheral atherosclerosis 27 (9.6) 33 (9.8) 0.950
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Table 4
Two loci analysis. CFH and LOC 387715 interactions
OR (95 % CI)
rs10490924
G/G G/T T/T Interaction P
rs1329421
A/A 1 4.3 (8.2–2.3) 13.2 (39–4.5) 0.99871
A/T 2.3 (4–1.3) 9.1 (17–4.9) 33.1 (101.5–10.8)
T/T 3.9 (7.9–1.9) 15 (31.7–7.1) 45.2 (362.8 – 5.6)
rs1329428
G/G 1 4.5 (7.7–2.6) 12.3 (36.8–4.1) 0.79878
A/G 0.6 (1–0.4) 2.7 (4.6–1.3)5 10.7 (37.4–3.1)
A/A 0.2(0.6–0.1) 0.5 (1.3–0.2) 0.8 (5.12–0.13)
rs3766404
T/T 1 3.9 (5.8–2.5) 13 (31.7–5.4) 0.64755
C/T 0.4 (0.7–0.2) 2.6 (5.4–1.3) 5.4 (16.7–1.7)
C/C 0.4 (3.2–0.04) 0.6 (2.4–0.2) NA
rs1831282
T/T 1 3.9 (7.5–2) 10.6 (32–3.5) 0.9939
C/T 2.07 (3.7–1.2) 8.6 (16.3–4.5) 30.6 (94.8–9.8)
C/C 3.3 (6.7–1.7) 14.1 (29.3–6.8) 52.9 (420.4–6.6)
rs12144939
G/G 1 3.7 (5.8–2.4) 13.8 (36.1–5.2) 0.61646
G/T 0.5 (0.8–0.) 3 (1.5–5.8) 6.1 (18.7–2)
T/T 0.1 (1.1–0.02) 0.41 (1.5–0.1) 0 (NA–0)
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Table 5
Two locus analysis. FGF2 interactions with CFH and LOC387715
OR (95 % CI)
rs6820411
C/C C/A A/A Interaction P
CFH
 rs1329421
  A/A 1 2.2 (4.6–1.1) 0 (0-NA) 0.500
  A/T 2.1 (3.2–1.4) 3.7 (6.8–2) 3.3 (18.6–0.6)
  T/T 3.3 (5.6–2) 12.5 (37–4.2) NA
 rs1329428
  G/G 1 2.3 (4.4–1.2) 0.6 (9.2–0.04) 0.373
  A/G 0.5 (0.7–0.3) 1.1 (2.2–0.6) 1.1 (6.3–0.2)
  A/A 0.2 (0.34–0.1) 0.1 (0.5–0.02) NA
 rs3766404
  T/T 1 1.9 (3.1–1.2) 0.7 (3.6–0.1) 0.124
  C/T 0.4 (0.7–0.3) 1.1 (2.5–0.4) NA
  C/C 0.2 (0.7–0.05) NA NA
 rs1831282
  T/T 1 2.1 (4.4–1) NA 0.729
  C/T 2 (3–1.33) 3.8 (7.1–2.1) 2.2 (10.2–0.5)
  C/C 3.3 (5.5–2) 10.3 (28–3.8) NA
 rs12144939
  G/G 1 2.3 (3.9–1.4) 1.1 (6.4–.2) 0.836
  G/T 0.5(0.7–0.3) 1.1 (2.3–0.5) 1.4 (15.6–0.1)
  T/T 0.1 (0.5–0.04) 0.1 (1.2–0.02) NA
LOC387715
 rs10490924
  G/G 1 2.5 (4.5–1.4) 2.1 (10.9–0.5) 0.858
  G/T 4.1 (6.2–2.7) 8.7 (17–4.5) NA
  T/T 14.5 (31.9–6.6) 16.1 (72.1–3.6) NA
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